Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Isabelle Rieger"'
Autor:
Florence Joly, Claudia Lefeuvre-Plesse, Claire Garnier-Tixidre, Carole Helissey, Nathalie Menneveau, Alain Zannetti, Sebastien Salas, Nadine Houede, Sophie Abadie-Lacourtoisie, Laetitia Stefani, Soazig Nenan, Isabelle Rieger, Isabelle Durand-Zaleski, Jean-Marc Descotes, Amélie Anota
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Currently, oral targeted therapies are known to be effective and are frequently used to treat metastatic cancer patients, but fatigue is a frequently reported early side effect of these treatments. This fatigue may impact the pati
Externí odkaz:
https://doaj.org/article/8454578e57ce4e9ea28dc9f15cf6946e
Autor:
Sophie Abadie-Lacourtoisie, Isabelle Durand-Zaleski, Jean-Marc Descotes, C. Lefeuvre-Plesse, Nadine Houede, Nathalie Menneveau, Amélie Anota, Claire Garnier-Tixidre, Carole Helissey, Laetitia Stefani, Soazig Nenan, Florence Joly, Isabelle Rieger, Alain Zannetti, Sébastien Salas
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2020, 20 (1), ⟨10.1186/s12885-020-07381-4⟩
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer, BioMed Central, 2020, 20 (1), ⟨10.1186/s12885-020-07381-4⟩
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Background Currently, oral targeted therapies are known to be effective and are frequently used to treat metastatic cancer patients, but fatigue is a frequently reported early side effect of these treatments. This fatigue may impact the patient’s t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88e36ddbd2ce3c3709beb6cde705eb17
http://europepmc.org/articles/PMC7545839
http://europepmc.org/articles/PMC7545839
Autor:
Fabio Calabrò, Karim Fizazi, Gabriel Kacso, Stéphane Supiot, Raymond S. McDermott, Dominik Berthold, Aude Flechon, Ali Hasbini, Marie Laure Tanguy, Stéphanie Foulon, Gwenaelle Gravis, Guilhem Roubaud, Isabelle Rieger, Xavier Maldonado, Bertrand F. Tombal, Alberto Bossi, J. F. Berdah, Philippe Ronchin, Marlon Silva, Antoine Thiery-Vuillemin
Publikováno v:
Journal of Clinical Oncology. 39:5000-5000
5000 Background: Historically, androgen deprivation therapy (ADT) was the standard of care (SOC) for men with mCSPC. Since 2015, combining ADT with either docetaxel, novel hormonal therapies, or radiotherapy to the primary tumor (RXT) (for those with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6760f29f9b5ef1bb651d37c3538be932
https://doi.org/10.1200/jco.2021.39.15_suppl.5000
https://doi.org/10.1200/jco.2021.39.15_suppl.5000